News

October 7, 2016October 7, 2016

Baricitinib Shows Promise as Potential New Treatment for Rheumatoid Arthritis, Study Shows

News

Treatment with baricitinib improves joint damage in patients with rheumatoid arthritis (RA) who have an inadequate response or intolerance to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), according to the results of ... Read more

October 5, 2016October 5, 2016

Stimulating Environment Boosted Immune System in Mice; RA applications envisioned

News

It may be possible to boost the immune system simply by staying in a stimulating environment, according to a study that showed giving mice more toys and space for two ... Read more

October 3, 2016October 3, 2016

Potential RA Therapy, CT-P10, Seen in Study to Be Biosimilar to Rituxan

News

In a Phase 1 clinical trial, researchers showed that CT-P10 is a biosimilar to Rituxan (rituximab), a current treatment of choice for rheumatoid arthritis (RA) patients who fail to respond to ... Read more

September 30, 2016September 30, 2016

Non-TNF Therapy Seen as Best for Rheumatoid Arthritis Patients Who Don’t Respond to Anti-TNF Treatment

News

Non-tumor necrosis factor (TNF) drugs are more effective than anti-TNF drugs in some patients with rheumatoid arthritis, according to the results of a clinical trial that were published in the ... Read more

September 28, 2016September 28, 2016

European Medicines Agency Issues Positive Opinion for Cimzia AutoClicks Prefilled Pen

News

UCB announced that its Cimzia (certolizumab pegol) AutoClicks Prefilled Pen has been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The CHMP positive opinion designation concerning ... Read more

September 26, 2016September 26, 2016

GSK Submits Rheumatoid Arthritis Treatment Sirukumab for EU Marketing Authorization

News

GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product sirukumab, a subcutaneous formulation for adults with moderate to severe rheumatoid arthritis (RA). The ... Read more

September 23, 2016September 23, 2016

EU Commission Approves Orencia for RA Patients in Combination with Methotrexate

News

The European Commission has approved the use of Orencia (abatacept) by intravenous infusion and injection in combination with methotrexate (MTX) to treat highly active and progressive rheumatoid arthritis (RA) in ... Read more

September 12, 2016September 12, 2016

AANP Asks Patients and Providers Alike to Ensure Chronic Pain Is Properly Treated

News

The American Association of Nurse Practitioners (AANP) is asking patients and healthcare providers alike to help stop chronic pain from being insufficiently treated by improving patient-provider communication, and by working to strengthen awareness ... Read more

September 7, 2016September 7, 2016

Investigational Treatment Improves Refractory Rheumatoid Arthritis in Clinical Study

News

Mesoblast Limited’s mesenchymal precursor cell (MPC) product candidate MPC-300-IV is well tolerated and results in a dose-dependent improvement in clinical symptoms, physical function, and disease activity in patients with refractory rheumatoid ... Read more

September 2, 2016September 2, 2016

Erelzi, a Biosimilar to Enbrel, Approved by FDA for Rheumatoid Arthritis, Other Inflammatory Diseases

News

The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Erelzi (etanercept-szzs) for a number of inflammatory diseases, including rheumatoid arthritis (RA). Erelzi, a TNF inhibitor, was approved as a biosimilar to ... Read more